Analysis Appears to Debunk Paclitaxel-Coated Device Risk in PAD

VOYAGER-PAD finds no excess mortality or amputation risk with paclitaxel-coated devices When a 2018 meta-analysis of 28 trials reported "a significant relationship" between exposure to paclitaxel via a drug-eluting stent used to treat peripheral artery disease (PAD) and excess mortality, the FDA responded by first issuing a warning letter, followed by a second letter urging

Related Keywords

Colorado ,United States ,Germany ,Boston ,Massachusetts ,Sweden ,Bad Krozingen ,Baden Wüberg ,Swedish ,Thomas Zeller ,Peggy Peck ,Connien Hess ,Valentin Fuster ,Amgen ,Industry Consortium Medtronic ,Division Of Cardiology ,Boston Scientific ,Philips ,University Heart Center Freiburg ,Gore Associates ,University Of Jena ,University Of Colorado School Medicine ,Journal Of The American College Cardiology ,Clinical Research ,Boston Scientific Corp ,Janssen Pharmaceuticals ,Medtronic ,Department Of Medicine ,American College ,Mount Sinai Heart ,Physician In Chief Mount Sinai Hospital ,Colorado School ,Swedish Drug Elution Trial ,Peripheral Arterial Disease ,Pan Industry Consortium ,Abbott Vascular ,Cook Medical ,Vesper Medical ,Bard Peripheral Vascular ,Armed Alliance ,Intact Vascular ,